Tag Archives: biotech industry

Indiana Governor Signs Bill that Supports Transparent Communication

admin-ajax copy

Indiana Governor Mike Pence has signed bipartisan legislation enabling retail pharmacies within his state to substitute interchangeable biologic medicines, once approved, for the innovator drug on which they are based. Not only does this legislation empower pharmacists to use their professional discretion to automatically substitute interchangeable biologic medicines, it also ensures transparent communication within a patient’s entire health care team to ensure the best decisions possible. The newly signed Senate Bill 262 ensures pharmacists communicate with the Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

GM Crop Technology Provides Boost to Developing Country Farmers

Canola-115x76

Millions of farmers around the world continue to choose to plant and replant genetically modified (GM) crop varieties because of their environmental and socio-economic benefits and the important role they play in maintaining food security, according to a new study. The report, Global Status of Commercialized Biotech/GM Crops: 2013, released annually by the International Service for the Acquisition of Agri-Biotech Applications (ISAAA), says a record 18 million farmers in 27 countries are growing biotech crops on Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

#BIOCEO14: An Optimistic Outlook for 2014

Panel

The 16th Annual BIO CEO & Investor Conference​ concluded with a lively Closing Plenary Session examining the current capital market for IPOs, where the industry has been and where it’s headed in 2014. The panel unanimously agreed: 2013 was the year of the IPO. In total, 56 healthcare companies priced an IPO; 43 of these were biotech companies. Last year was the strongest IPO year since 2000 and the second strongest in history with over $10 Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

4 Tips for Building a Successful Biotech: Richard Pops of Alkermes at #BIOCEO14

Pops

The 16th Annual BIO CEO & Investor Conference opened with a fireside chat between Richard F. Pops, Chairman & Chief Executive Officer of Alkermes, and David Gluckman of Lazard. The candid discussion gave biotech CEOs a peek in to the story of Alkermes, yielding useful guidance on building a successful, agile company ready for a changing marketplace. Here are some of the highlights: Be world class in a specific area of science. “In our company, Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Fewer Small Public Biotechs Today

Fig2-size-2008-vs-2013-115x76

A lot can happen in six years. The number of active biotech companies currently trading on US exchanges is now only 300. At the start of 2008, there were almost 400 active companies.   The net decrease in the number of active companies since 2008 is 24%. Had it not been for all the IPO activity we have seen this year, the decrease would have been substantially more. In fact, only 55% of the original Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,